---
input_text: 'DUETTE: a phase II randomized, multicenter study to investigate the efficacy
  and tolerability of a second maintenance treatment in patients with platinum-sensitive
  relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose)
  polymerase (PARP) inhibitor maintenance treatment. BACKGROUND: With the success
  of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the first-line and second-line
  treatment settings, a new patient population is emerging with platinum-sensitive
  relapsed ovarian cancer, who have previously received a PARP inhibitor in the maintenance
  setting and for whom no second maintenance standard of care exists. DUETTE (NCT04239014)
  will evaluate the combination of ceralasertib (a potent, selective inhibitor of
  the serine/threonine kinase ataxia telangiectasia and Rad3-related protein (ATR)
  + olaparib, or olaparib monotherapy, compared with placebo, in this patient population
  of unmet need. PRIMARY OBJECTIVE: The primary objective is to assess the efficacy
  of ceralasertib + olaparib combination, and olaparib monotherapy, compared with
  placebo, as second maintenance therapy in platinum-sensitive relapsed ovarian cancer.
  STUDY HYPOTHESIS: This study will test the hypothesis that ceralasertib + olaparib,
  or olaparib monotherapy, is tolerable, and effective at prolonging progression-free
  survival compared with placebo. TRIAL DESIGN: This is a phase II, multicenter study
  where patients will be randomized in a 1:1:1 ratio to receive either (Arm 1) ceralasertib
  + olaparib, (Arm 2) olaparib monotherapy, or (Arm 3) placebo. The olaparib and placebo
  arms will be double-blinded, whereas the ceralasertib + olaparib arm will be open
  label. Patients will be stratified according to BRCA status, and response to platinum-based
  chemotherapy. MAJOR INCLUSION/EXCLUSION CRITERIA: Eligible patients will have histologically
  diagnosed high-grade epithelial ovarian cancer, with platinum-sensitive relapse
  on, or after, completion of at least 6 months of any prior PARP inhibitor maintenance
  therapy (a minimum of 12 months is required if the patient received PARP inhibitor
  maintenance following first-line chemotherapy). If the prior PARP inhibitor used
  was olaparib then patients must have received treatment without significant toxicity
  or the need for a permanent dose reduction. Disease relapse in the second-line or
  third-line setting is allowed. Patients who have received secondary debulking surgery
  are potentially eligible if they meet all other inclusion criteria. PRIMARY ENDPOINTS:
  The primary endpoint is progression-free survival determined by blinded independent
  central review according to RECIST 1.1, with sensitivity analysis of progression-free
  survival using investigator assessments according to RECIST 1.1. SAMPLE SIZE: 192
  patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: December
  2022. TRIAL REGISTRATION: NCT04239014.'
raw_completion_output: |-
  primary_disease: epithelial ovarian cancer

  medical_actions: second maintenance treatment; ceralasertib + olaparib combination; olaparib monotherapy; platinum-based chemotherapy; secondary debulking surgery

  symptoms: platinum-sensitive relapsed

  chemicals: poly(ADP-ribose) polymerase (PARP) inhibitors; ceralasertib; olaparib

  action_annotation_relationships: second maintenance treatment PREVENTS platinum-sensitive relapsed IN epithelial ovarian cancer; ceralasertib + olaparib combination TREATS platinum-sensitive relapsed IN epithelial ovarian cancer (with ceralasertib, olaparib); olaparib monotherapy TREATS platinum-sensitive relapsed IN epithelial ovarian cancer (with olaparib); platinum-based chemotherapy TREATS platinum-sensitive relapsed IN epithelial ovarian cancer; secondary debulking surgery TREATS platinum-sensitive relapsed IN epithelial ovarian cancer
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  secondary debulking surgery TREATS platinum-sensitive relapsed IN epithelial ovarian cancer

  ===

extracted_object:
  primary_disease: MONDO:0005140
  medical_actions:
    - second maintenance treatment
    - ceralasertib + olaparib combination
    - olaparib monotherapy
    - platinum-based chemotherapy
    - secondary debulking surgery
  symptoms:
    - platinum-sensitive relapsed
  chemicals:
    - CHEBI:62913
    - CHEBI:231342
    - CHEBI:83766
  action_annotation_relationships:
    - subject: second maintenance treatment
      predicate: PREVENTS
      object: relapsed
      qualifier: MONDO:0005140
      subject_extension: second maintenance treatment
      object_extension: platinum-sensitive
    - subject: combination
      predicate: TREATS
      object: HP:0025318
      subject_qualifier: with ceralasertib, olaparib
      subject_extension: ceralasertib + olaparib
      object_extension: platinum-sensitive relapsed
    - subject: olaparib monotherapy
      predicate: TREATS
      object: HP:0025318
      qualifier: platinum-sensitive relapsed
      object_qualifier: with olaparib
      subject_extension: CHEBI:83766
      object_extension: platinum-sensitive relapsed
    - subject: <chemotherapy>
      predicate: <TREATS>
      object: <relapsed>
      qualifier: <epithelial ovarian cancer>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <platinum-based>
      object_extension: <platinum-sensitive>
    - subject: secondary debulking surgery
      predicate: TREATS
      object: platinum-sensitive relapsed
      qualifier: MONDO:0005140
named_entities:
  - id: MONDO:0005086
    label: Renal cell carcinoma
  - id: MONDO:0003060
    label: Biliary tract cancer (BTC)
  - id: CHEBI:175901
    label: Gemcitabine
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0008840
    label: Ataxia Telangiectasia
  - id: MAXO:0010030
    label: Bone Marrow Transplantation
  - id: MAXO:0001001
    label: Gene Therapy
  - id: CHEBI:166830
    label: Acetyl-DL-leucine
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:4462
    label: Dexamethasone sodium phosphate
  - id: CHEBI:133021
    label: venetoclax
  - id: HP:0002721
    label: Immunodeficiency
  - id: HP:0002073
    label: progressive cerebellar ataxia
  - id: HP:0002013
    label: vomiting
  - id: HP:0002315
    label: headache
  - id: CHEBI:27899
    label: cisplatin
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001875
    label: Neutropenia
  - id: CHEBI:231342
    label: Ceralasertib
  - id: CHEBI:31355
    label: Carboplatin
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MONDO:0005184
    label: Pancreatic ductal adenocarcinoma (PDAC)
  - id: HP:0020174
    label: Drug resistance
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0010150
    label: Head and neck squamous cell carcinomas (HNSCC)
  - id: MAXO:0000014
    label: Radiotherapy (RT)
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0002015
    label: Dysphagia
  - id: MONDO:0008876
    label: Bloom Syndrome (BS)
  - id: HP:0001510
    label: growth retardation
  - id: HP:0011793
    label: malignancies
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: CHEBI:27656
    label: Camptothecin (CPT)
  - id: CHEBI:63632
    label: Topotecan
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:231344
    label: Talazoparib
  - id: CHEBI:231616
    label: M4344
  - id: MONDO:0008433
    label: Small-cell lung cancer (SCLC)
  - id: HP:0030357
    label: Small-cell lung cancer (SCLC)
  - id: MONDO:0003778
    label: Inborn Errors of Immunity (IEI)
  - id: HP:0033141
    label: Severe SARS-CoV-2 infection
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:22907
    label: Bleomycin (BLM)
  - id: MONDO:0005494
    label: Triple-negative breast cancer (TNBC)
  - id: CHEBI:9555
    label: 6-thioguanine
  - id: CHEBI:4659
    label: Disulfiram
  - id: CHEBI:28694
    label: Cu
  - id: CHEBI:83766
    label: Olaparib
  - id: HP:0002894
    label: pancreatic cancer
  - id: MONDO:0005192
    label: Pancreatic Cancer
  - id: MONDO:0007254
    label: Breast Cancer
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0003002
    label: Breast Cancer
  - id: MONDO:0008903
    label: lung cancer
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0005070
    label: Tumors
  - id: MAXO:0001394
    label: Oral administration
  - id: MONDO:0036501
    label: Refractory Cancer
  - id: CHEBI:45863
    label: Paclitaxel
  - id: MONDO:0018177
    label: Glioblastoma
  - id: MAXO:0000004
    label: Surgery
  - id: HP:0012174
    label: Glioblastoma
  - id: MONDO:0009807
    label: Osteosarcoma
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:132992
    label: radiosensitizers
  - id: MONDO:0005575
    label: colorectal cancer
  - id: CHEBI:62913
    label: poly (ADP-ribose) polymerase (PARP) inhibitors
  - id: HP:0010310
    label: Chylothorax
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:27563
    label: Arsenic
  - id: CHEBI:229924
    label: pifithrin-alpha (PFTalpha)
  - id: CHEBI:29678
    label: Sodium arsenite (NaAsO2)
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MONDO:0004986
    label: Bladder cancer
  - id: HP:0009725
    label: Bladder cancer
  - id: MONDO:0968974
    label: Large B-Cell Lymphoma (LBCL)
  - id: MAXO:0000381
    label: Lymph node biopsy
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:8382
    label: Prednisone
  - id: MONDO:0005623
    label: AT (Autoimmune Thyroiditis)
  - id: MONDO:0008315
    label: Prostate Cancer
  - id: CHEBI:4672
    label: Docetaxel
  - id: HP:0012125
    label: Prostate Cancer
  - id: CHEBI:50914
    label: PI3K inhibitors
  - id: CHEBI:34936
    label: di-phenoxy acetamide (DPA) analogs
  - id: CHEBI:25555
    label: Compound DPA (7n)
  - id: HP:0000988
    label: rash
  - id: CHEBI:31348
    label: capecitabine
  - id: CHEBI:16044
    label: MET
  - id: HP:0100526
    label: Lung cancer
  - id: MONDO:0019600
    label: Xeroderma pigmentosum (XP)
  - id: CHEBI:131808
    label: Thymidine dimers
  - id: CHEBI:28300
    label: Glutamine
  - id: CHEBI:16856
    label: Glutathione
  - id: CHEBI:16810
    label: Alpha-ketoglutarate
  - id: HP:0000657
    label: Oculomotor apraxia
  - id: HP:0001266
    label: Choreoathetosis
  - id: CHEBI:4806
    label: Epigallocatechin-3-gallate (EGCG)
  - id: CHEBI:16240
    label: H2O2
  - id: CHEBI:229722
    label: RP-3500
  - id: CHEBI:135702
    label: Belotecan
  - id: CHEBI:229661
    label: Omaveloxolone
  - id: CHEBI:8863
    label: riluzole
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0005140
    label: Epithelial ovarian cancer
  - id: HP:0002018
    label: Nausea
  - id: HP:0012378
    label: Fatigue
  - id: HP:0002039
    label: Anorexia
  - id: MONDO:0005233
    label: Non-small cell lung cancer
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: CHEBI:3077
    label: Betamethasone
  - id: CHEBI:30884
    label: Glucocorticoids (GCs)
  - id: MONDO:0024331
    label: Colorectal Cancer (CRC)
  - id: MONDO:0005061
    label: Lung adenocarcinoma (LUAD)
  - id: HP:0030078
    label: Lung adenocarcinoma
  - id: HP:0025318
    label: epithelial ovarian cancer
